摘要
卡巴他赛是一种新型紫杉烷类抗肿瘤药物,对于多西他赛治疗无效的、激素难治性、转移性前列腺癌患者效果显著。虽然作为临床二线用药,但由于卡巴他赛对P-糖蛋白的低黏附性以及良好的药动学特性,使其具有较大的应用潜力,近年来越来越受到研究者们的关注。本文结合国内外研究进展,以卡巴他赛的药理作用、不良反应为出发点,对其用于前列腺癌治疗的递药系统研究进行综述。
Cabazitaxel is a new taxane-based anti-tumor drug, which has a significant effect on hormone refractory metastatic prostate cancer patients who are ineffective to docetaxel. Although cabazitaxel is used as a second-line clinical drug, it has great application potential due to its low adhesion to P-glycoprotein and good pharmacokinetic characteristics. In recent years, researchers are paying more attention to it. Based on the research progress achieved both at home and abroad and with the pharmacological effects and adverse drug reactions as the starting point, a comprehensive review was made in the drug delivery system of cabazitaxel for treatment of prostate cancer.
作者
万众
孙治国
鲁莹
王林辉
WAN Zhong;SUN Zhiguo;LU Ying;WANG Linhui(Department of Urology, Changzheng Hospital, Navy Military Medical University, Shanghai 200003,China;Teaching and Research Section of Pharmaceutics, School of Pharmacy, Navy Military Medical University, Shanghai 200433,China)
出处
《药学服务与研究》
CAS
2019年第2期121-124,共4页
Pharmaceutical Care and Research
关键词
卡巴他赛
前列腺癌
递药系统
药理作用
药物副反应报告系统
综述
cabazitaxel
prostate cancer
drug delivery system
pharmacological effects
adverse drug reactions reporting system
review